Frequency Of Antimicrobial Resistance Markers ...

Our Experiences On Urgent Abdominal Relaparot...

Variation Of Peak Expiratory Flow Rate With Bod...

Evaluation And Imagery Of Cold Pain In Cpm

Anesthesia And Physician Payment Reform

0 votes
Nitric Oxide: A Small Molecule With Diversifying Impacts
Author: Arun Kumar And Minaketan Tripathy
Publisher: Internet Medical Publishing
2 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Dissertation
DOI: 10.3823/1007
Follow this publisher

Share this publication:


Ever since Nitric oxide (NO) was discovered it has been the most studied molecule as it had so much diversity in its biological function based on organ and site specificity. It has been evolved as an important physiological mediator involved in cellular signaling in the cardiovascular, gastrointestinal, genitourinary, respiratory and nervous system. It’s failure to be in normal range have been indicated as a cause of various diseases. The drug designing and its therapeutic efficacy is based on the production and inhibition of NO. The main areas of its involvement are in neurotransmission, nonspecific immunity and inflammatory response and its regulation in blood pressure.

It has both beneficial and deleterious effects, of which beneficial effects includes the inhibition of leukocyte adhesion, protection against tumor necrosis factor, and also its role an as antioxidant such as offering protection against hydrogen peroxide, and many more. Its deleterious effects include the cytotoxic effects, inhibition of enzyme functions, induction of DNA damage, lipid peroxidation, etc. On the basis of enormous work that has been done on NO’s , presumes it as a double edge sword mediator, which has beneficial physiological effects as well as detrimental pathological effect making its development into a drug quite challenging. So there is a tremendous potential in the field of NO research, so that NO can be further regulated by pharmaceuticals and can be further exploited for treatment using NO or the regulators of NO.

About the publisher:

iMedPub Limited is a publishing house registered in UK, publishing medical books and journals since 2005. As an open service to doctors and biomedical researchers, it is driven by clinicians and researchers for themselves, while serving the interests of the general public. iMedPub disseminates research in a tiered system, beginning with our specialty books and journals and then working upwards. The grand vision of iMedPub is a world where all medical researchers and health professionals have an equal opportunity to seek, share and create knowledge. As we are a low cost academic publisher we offer the lowest article processing charges of all biomedical journals and publish books free of charges for authors.

Select a payment method